Engineered Bacterial Outer Membrane Vesicles‐Based Doxorubicin and CD47‐siRNA Co‐Delivery Nanoplatform Overcomes Immune Resistance to Potentiate the Immunotherapy of Glioblastoma
Advanced Materials · 2025-04 · 37 (15)
DOI: 10.1002/adma.202418053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 04.03.2025. Verfasst von Haoyu You und 19 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Smart Drug Delivery/Innovative Center for New Drug Development of Immune Inflammatory Diseases (Ministry of Education), Minhang Hos…. Hauptthemen laut MEDLINE: Glioblastoma, Doxorubicin, RNA, Small Interfering, Immunotherapy. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Natural Science Foundation of Shanghai Science and Technology Innovation Plan.
Abstract (Originalsprache)
Apart from the blood‐brain barrier (BBB), the efficacy of immunotherapy for glioblastoma (GBM) is limited by the presence of intrinsic and adaptive immune resistance, implying that co‐delivery of various immunotherapeutic agents or simultaneous regulation of different cells is urgently needed. Bacterial outer membrane vesicles (OMVs) offer a unique advantage in the treatment of GBM, owing to their multifunctional properties as carriers and immune adjuvants and their ability to cross the BBB. However, traditional OMVs can lead to toxic side effects and disruption of tight junctions in the BBB. Therefore, to enhance the in vivo safety and targeting capability of OMVs, we introduced engineered OMVs to reduce toxicity and further constructed a modularly assembled nanoplatform by performing simple peptide modifications. This nanoplatform demonstrates satisfactory biosafety and is able to continuously cross the BBB and target GBM with the assistance of Angiopep‐2. Subsequently, immunogenic substances on OMVs, along with carried small‐interfering RNA (siRNA) and doxorubicin, can promote and enhance the reprogramming and phagocytic abilities of macrophages and microglia, respectively, and increase the immunogenicity of GBM, ultimately overcoming GBM immune resistance to enhance the efficacy of immunotherapy. This OMVs‐based nanoplatform provides a new paradigm and insights into the development of immunotherapy for GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Smart Drug Delivery/Innovative Center for New Drug Development of Immune Inflammatory Diseases (Ministry of Education), Minhang Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers…
- Department of Digestive Diseases, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, China.
- Quzhou Fudan Institute, Quzhou, 324003, China.
ORCID-Profile: Tao Sun
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai Science and Technology Innovation Plan
- Shanghai Municipal Science and Technology Major Project
- National Key Research and Development Program of China
Zitieren
APA
You, H., Zhang, S., Zhang, Y., Chen, Q., Wu, Y., Zhou, Z., Zhao, Z., Su, B., Li, X., Guo, Y., Chen, Y., Tang, W., Liu, B., Fan, H., Geng, S., Fang, M., Li, F., Liu, G., Jiang, C., & Sun, T. (2025). Engineered Bacterial Outer Membrane Vesicles‐Based Doxorubicin and CD47‐siRNA Co‐Delivery Nanoplatform Overcomes Immune Resistance to Potentiate the Immunotherapy of Glioblastoma. Advanced Materials, 37(15). https://doi.org/10.1002/adma.202418053
Vancouver
You H, Zhang S, Zhang Y, Chen Q, Wu Y, Zhou Z, et al. Engineered Bacterial Outer Membrane Vesicles‐Based Doxorubicin and CD47‐siRNA Co‐Delivery Nanoplatform Overcomes Immune Resistance to Potentiate the Immunotherapy of Glioblastoma. Advanced Materials. 2025;37(15). doi:10.1002/adma.202418053
BibTeX
@article{You2025,
author = {You, Haoyu and Zhang, Shilin and Zhang, Yiwen and Chen, Qinjun and Wu, Yuxing and Zhou, Zheng and Zhao, Zhenhao and Su, Boyu and Li, Xuwen and Guo, Yun and Chen, Yun and Tang, Weiyi and Liu, Bing and Fan, Hongrui and Geng, Shuo and Fang, Mingzhu and Li, Fangxin and Liu, Guangna and Jiang, Chen and Sun, Tao},
title = {Engineered Bacterial Outer Membrane Vesicles‐Based Doxorubicin and CD47‐siRNA Co‐Delivery Nanoplatform Overcomes Immune Resistance to Potentiate the Immunotherapy of Glioblastoma},
journal = {Advanced Materials},
year = {2025},
volume = {37},
number = {15},
doi = {10.1002/adma.202418053}
}
EUVIMED